Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers

Breast Cancer

Volumn 21, Issue 1, 2014, Pages 47-51

  Hayashi, Satoshi ^a   Kitada, Masahiro ^a   Sato, Kazuhiro ^a   Matsuda, Yoshinari ^a   Ishibashi, Kei ^a   Oikawa, Kensuke ^a   Miyokawa, Naoyuki ^a   Hirata, Satoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Breast cancer; Histological grade; Ki67 labeling index; Subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KI67 LABELING INDEX; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84891557313     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0353-2     Document Type: Article

References (13)

1. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-5.
2. de Azambuja E, Cardoso F, de Castro G, Colozza M Jr, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504-13.
3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
4. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
6. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
7. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labeling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 2011;127:591-9.
8. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, South Sweden Breast Cancer Group. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol. 2010;23:251-9.
9. Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, Domingues MA, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol. 2008;39:720-30.
10. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer. 2005;41:2924-34.
11. Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X. Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast. 2008;17:172-9.
12. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-904.
13. Fasching PA, Heusinger K, Haberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.